Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaySearch Laboratories ABCHIX:RAYBS 93 Return-on-Tangible-Asset is 14.76% as of Mar. 2026, which is 61% above its 10-year median of 9.17. GuruFocus rates CHIX:RAYBS with a GF Score™ of 93/100 and a GF Value™ of kr182.08 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 680 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 91.47% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. RaySearch Laboratories AB's annualizedNet Income for the quarter that ended in Mar. 2026 was kr213 Mil. RaySearch Laboratories AB's average total tangible assets for the quarter that ended in Mar. 2026 was kr1,442 Mil. Therefore, RaySearch Laboratories AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 14.76%.
The historical rank and industry rank for RaySearch Laboratories AB's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:RAYBs'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -4.69 Med: 9.17 Max: 39.67
Current: 15.55
During the past 13 years, RaySearch Laboratories AB's highest Return-on-Tangible-Asset was 39.67%. The lowest was -4.69%. And the median was 9.17%.
CHIX:RAYBs's Return-on-Tangible-Asset is ranked better than 91.47% of 680
companies
in the Healthcare Providers & Services industry
Industry Median: 2.505
vs CHIX:RAYBs: 15.55
RaySearch Laboratories AB (CHIX:RAYBs) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
RaySearch Laboratories AB Return-on-Tangible-Asset Related Terms
RaySearch Laboratories AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for RaySearch Laboratories AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB Return-on-Tangible-Asset Chart
CHIX:RAYBS vs VEEV, BTSG, TEM: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 14.76% mean?
RaySearch Laboratories AB (CHIX:RAYBS) has a Return-on-Tangible-Asset of 14.76% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RaySearch Laboratories AB and its competitors. This is 61% above median its historical median of 9.17. According to the industry distribution chart, RaySearch Laboratories AB ranks #58 out of 680 companies in the Healthcare Providers & Services industry, placing it in the top 8.5%.
Is RaySearch Laboratories AB's Return-on-Tangible-Asset too high?
RaySearch Laboratories AB's current Return-on-Tangible-Asset of 14.76% is 61% above median its 10-year median of 9.17. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.51. RaySearch Laboratories AB's value of 14.76% is 489.2% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #58 out of 680 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #58 out of 680 companies for Return-on-Tangible-Asset. This places RaySearch Laboratories AB in the top 9% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.51. RaySearch Laboratories AB's value of 14.76% is 489.2% above this benchmark. While the company's 10-year median is 9.17 vs. the industry median of 2.51, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.51, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Return-on-Tangible-Asset of 14.76% is 489.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Return-on-Tangible-Asset is 14.76%, which is 61% above median its own 10-year median of 9.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr182.08, compared to a current price of kr234.70 — trading 28.9% above its estimated fair value. The current Return-on-Tangible-Asset is 14.76%, which is 61% above median its 10-year median of 9.17 and 489.2% above the Healthcare Providers & Services industry median of 2.51. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Return-on-Tangible-Asset is 14.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of kr234.70 is trading 28.9% above its estimated GF Value™ of kr182.08.
GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.
Key valuation signals for CHIX:RAYBS:
Return-on-Tangible-Asset: 14.76% (61% above median its 10-year median of 9.17)
GF Value™: kr182.08 vs. price of kr234.70 (28.9% above fair value)
Industry Position: 489.2% above the Healthcare Providers & Services median (#58 of 680)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score
Get the complete analysis for CHIX:RAYBS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
